BirchBioMedRevised terms
BirchBioMed revises its direct-listing terms
BirchBioMed revises its direct-listing terms (October 9, 2026).
BirchBioMed is a clinical-stage biopharmaceutical company developing treatments for scarring (fibrosis) and related skin disorders, certain autoimmune diseases, and organ fibrosis.
The revised prospectus registers common shares for resale in connection with a direct listing on the Nasdaq Global Market.
Offering details
- Shares registered for resale
- 30.8M
Changes to the terms
| Metric | Previously disclosed (2026-08-12) | This announcement (2026-10-09) |
|---|---|---|
| Shares registered for resale | 29.9M | 30.8M |
Listing timeline
files for a direct listing
BirchBioMed
revises its direct-listing terms
BirchBioMed